Capmatinib, a new drug for the treatment of METex14 mutated lung cancer

Capmatinib is a new targeted anti-cancer drug developed by Novartis, a world-renowned pharmaceutical company. Its trade name is Tabrecta and it has emerged in the field of cancer treatment. This drug is a highly selective MET inhibitor, specially designed for tumor patients with abnormalities in the MET signaling pathway. Abnormalities of the MET gene, including mutations or amplifications, have been proven to be closely related to the occurrence and development of various cancers, among which non-small cell lung cancer (NSCLC) is one of them.

Capmatinib, with its unique mechanism, can precisely inhibit the activity of MET, thereby effectively blocking the crazy proliferation and spread of cancer cells that are late or metastatic and carry MET exon 14 skipping mutations (METex14 skipping mutation) brings new treatment hope to patients with NSCLC. This specific mutation, although relatively rare in NSCLC patients, is closely associated with poor patient prognosis and resistance to traditional treatments. The advent of capmatinib is precisely to fill this treatment gap and to achieve precise treatment after confirming the patient's mutation type through genetic testing.

As a highly selective MET tyrosine kinase inhibitor, capmatinib can not only effectively inhibit the MET signaling pathway and reduce the growth, migration and invasion of cancer cells, it can also have a positive impact on the tumor microenvironment and enhance patients' sensitivity to other treatments. This unique mechanism enables capmatinib to demonstrate extremely high therapeutic specificity and significant efficacy in the treatment of tumors with METex14 skip mutations.

Clinical trial data show that capmatinib has demonstrated impressive anti-tumor activity in patients with METex14 skip mutationsNSCLC, with an overall response rate (ORR) exceeding 40%. Of course, any drug may be accompanied by certain side effects, and capmatinib is no exception. Common ones include nausea, vomiting, fatigue, abnormal liver function, and edema. Overall, capmatinib was well tolerated by patients.

Capmatinib is the first targeted drug specifically targeting METex14 jumping mutations, and its advent is undoubtedly a milestone. It not only provides new treatment options for these patients, but also brings the dawn of life, especially for those patients who are resistant or ineffective with traditional treatments. With the continuous deepening of research on MET, we have reason to believe that capmatinib will play an important role in the treatment of more types of cancer in the future.

xa0

References

Novartis official website:https://www.novartis.com